The drug, although classified as an anabolic, however, androgenic side effects can occur. For example, perhaps increasing the oiliness of the skin, acne, hair growth on the body and face. Therefore, to avoid these unpleasant consequences, it should be strictly comply with the recommendations on the dosage of the drug. Women should be aware of the possible consequences virialization while taking the drug. In this case, they can have unpleasant phenomena such as voice. This coarse with low androgenic activity, androgenic side effects are much greater than threshold testosterone or fluoxymesterone methandrostenolone the. Do not forget that the drug can reduce the production of natural male libido and testosterone in the body. Reductase inhibitors should not be taken in the course nandrolone, as this may result in the exacerbation of side effects and impairment of general physical condition of the athlete.
Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid , found naturally in valerian .  Valproic acid is a carboxylic acid , a clear liquid at room temperature. For many decades, its only use was in laboratories as a "metabolically inert" solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol -induced convulsions in laboratory rats .  It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide.  Valproic acid has also been used for migraine prophylaxis and bipolar disorder. 
Dienogest was synthesized in 1979 in Jena , Germany under the leadership of Prof. Kurt Ponsold, was initially referred to as STS-557 .   It was found that its potency was 10 times that of levonorgestrel .  The first product on the market to contain dienogest was a combined oral contraceptive pill (with ethinylestradiol), Valette, introduced in 1995 and made by Jenapharm .  In 2007, dienogest was introduced as Dinagest in Japan for the treatment of endometriosis, and it was subsequently marketed for this indication as Visanne in Europe and Australia in December 2009 and April 2010, respectively.  Qlaira was introduced in Europe in 2009 and Natazia was introduced in the United States in 2010.